Page last updated: 2024-11-05

methyl nitrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methyl nitrate: C-H3-N-O3 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11724
MeSH IDM0379976

Synonyms (19)

Synonym
methyl nitrate
nitric acid, methyl ester
einecs 209-941-3
brn 1699872
methyl nitrate [forbidden]
methylester kyseliny dusicne [czech]
FT-0654167
nitric acid methyl ester
A832511
598-58-3
unii-lad9rt85es
lad9rt85es ,
methylester kyseliny dusicne
4-01-00-01254 (beilstein handbook reference)
methyl nitrate [mi]
ch3ono2
DTXSID4073205
FT-0700094
Q425393
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (27.78)18.7374
1990's0 (0.00)18.2507
2000's9 (50.00)29.6817
2010's4 (22.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.45 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.16 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]